Precigen gets FDA orphan drug status for PRGN-2012 in RRP
Precigen has secured orphan drug designation (ODD) for PRGN-2012 from the US Food and Drug Administration (FDA) in recurrent respiratory papillomatosis (RRP). PRGN-2012 is an investigational off-the-shelf (OTS) AdenoVerse immunotherapy. In January 2021, Precigen was given clearance by the FDA to launch a phase 1 study of PRGN-2012 AdenoVerse immunotherapy in adults having recurrent respiratory […]